Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than…
Browsing: non-small cell lung cancer
Drugs create balancing act for patients with non-small cell lung cancer
The results of a large, retrospective study of patients who received a form of immunotherapy…
BMS Announces EU approval of first-line treatment option for advanced non-small cell lung cancer
Bristol Myers Squibb (NYSE: BMY) announced that the European Commission (EC) has approved Opdivo (nivolumab)…
Clinical trial of selpercatinib shows strong response for patients with non-small cell lung cancer
An international team of researchers has found that selpercatinib, a drug that precisely targets cancers…
Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted…
IASLC WCLC 2020: Phase 3 eXalt3 study shows significantly longer progression-free survival in patients with ALK lung cancer
Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who…
Precision trial highlights need for new approach to treating genomically complex cancers
A pioneering lung cancer study, led by the University of Birmingham’s Cancer Research UK Clinical…
Unique cells found in lung cancer patients may predict survival
Size and number of fused cancer and immune cells linked to survival in non-small cell…
The Oncology Journal Club Episode 3: ASCO 2020 Review 1
The Oncology Podcast, brought to you by www.oncologynews.com.au, is proud to present the next episode…
ASCO 2020: Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping…